Bone Biologics (BBLG) Stock
Small biotech company focused on bone and tissue repair. Here's the price, business snapshot, and what's worth knowing about Bone Biologics in August 2026.
Bone Biologics Corp (BBLG) is a very small‑cap biotechnology company (market capitalisation about US$4.4m) that, according to public filings, focuses on biologic approaches related to bone and tissue repair. For investors, key considerations are its early‑stage profile, limited market float and dependence on clinical, regulatory and financing milestones to create value. Small market capitalisation typically means higher volatility, limited liquidity and a greater chance of dilution if the company raises capital. Potential upside drivers include positive clinical data, partnerships or licensing deals; downside risks include trial setbacks, regulatory hurdles and funding difficulties. This summary is educational only, not personalised advice. Investors should do further research, read recent filings, and consider their risk tolerance—small biotech stocks can experience rapid gains and steep losses.
About This Stock
BONE BIOLOGICS CORP
BBLG
Current Price
$0.64
Potential 12 Month Profit
1,109.92%
Sector
N/A
Industry
N/A
Ticker
BBLG
Market Cap
$1.76M
Potential 12 Month Profit
1,109.92%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Bone Biologics' stock, anticipating significant future price growth.
Financial Health
Bone Biologics Corp is showing good financial stability with solid book value and cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early‑stage catalysts
Clinical data, regulatory milestones or partner deals could move the stock, though outcomes are uncertain and can go either way.
Volatility & liquidity
Small market cap often means larger price swings and limited trading volume; be prepared for rapid moves and difficulty exiting positions.
Funding & partnerships
Access to capital or strategic collaborations can extend development plans, but funding needs may dilute shareholders if new equity is issued.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.